Pure Autonomic Failure: Clinical Trials

56 trials for Pure Autonomic Failure, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

31 completed, 10 terminated, 9 recruiting, 2 unknown. 17 Not applicable, 9 Phase 1, 8 Phase 3, 6 Phase 2, 3 Early Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable17Completed 10, Recruiting 7
Phase 19Completed 5, Terminated 2, Recruiting 1, Withdrawn 1
Phase 38Completed 5, Terminated 3
Phase 26Completed 3, Active not recruiting 1, Terminated 1, Unknown 1
Early Phase 13Terminated 2, Completed 1
Phase 41Completed 1

Follow Pure Autonomic Failure: new trials by email Literature Review of Pure Autonomic Failure trials Research Report on Pure Autonomic Failure

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Epidural Electrical Stimulation to Support Hemodynamic Management in Individuals With Parkinson's Disease
ARC-IM Investigational System - Hypotension Symptomatic, Parkinson's Disease
Not applicableRecruitingEcole Polytechnique Fédérale de Lausanne52025-07-032026-07-07
CO2 Rebreathing in nOH: A Proof-of-Concept Pilot Study
CO2 ReHaler - Neurogenic Orthostatic Hypotension, Autonomic Failure
Not applicableRecruitingUniversity of Calgary282024-07-302026-05-05
Prodromal Model of Parkinson's Disease Confined to The Peripheral Nervous System
Polyneuropathy, Alpha-Synucleinopathy
Enrolling by invitationUniversity of Aarhus1002024-05-132025-01-08
CPAP for the Treatment of Supine Hypertension
Active CPAP, Sham CPAP, Sleeping in a head-up tilt (HUT) position - Autonomic Failure, Pure Autonomic Failure
Not applicableRecruitingVanderbilt University Medical Center592022-06-232026-04-07
A Study of Lu AF82422 in Participants With Multiple System Atrophy
Lu AF82422, Placebo - Multiple System Atrophy
Phase 2Active not recruitingH. Lundbeck A/S642021-11-162026-04-13
Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms
Accelerometer, placebo pill, Midodrine or atomoxetine pill - Orthostatic; Hypotension, Neurogenic, Autonomic Failure
Not applicableRecruitingVanderbilt University Medical Center292021-02-052026-07-02
Synuclein-One Study
Skin Biopsy - Parkinson Disease, Multiple System Atrophy
CompletedCND Life Sciences4282021-01-042024-01-03
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
Midodrine, Placebo pill, Abdominal compression - Neurogenic Orthostatic Hypotension, Autonomic Failure
Early Phase 1CompletedVanderbilt University Medical Center312020-11-092026-08-07
Effect of Raised Head of the Bed on Lying Blood Pressure in Autonomic Failure
Tilt, Elevated trunk, Tilt - In home - Supine Hypertension, Autonomic Failure
Not applicableRecruitingVanderbilt University Medical Center442020-08-212026-10-22
[18F]F-DOPA Imaging in Patients With Autonomic Failure
[18F]FDOPA, Carbidopa 200mg oral dose, Entacapone 400mg oral dose - Autonomic Failure, Pure Autonomic Failure
Phase 1RecruitingDaniel Claassen402020-02-042026-03-16
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
ampreloxetine - Symptomatic Neurogenic Orthostatic Hypotension
Phase 3TerminatedTheravance Biopharma1102019-09-192022-11-30
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension, MSA
Phase 3TerminatedTheravance Biopharma2032019-02-222023-01-20
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension
Phase 3CompletedTheravance Biopharma1952019-01-242022-09-14
Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy
Deep brain stimulation - Multiple System Atrophy, Autonomic Failure
Not applicableCompletedUniversity of Oxford52018-09-092022-11-02
Clinical Laboratory Evaluation of Chronic Autonomic Failure
13N-Ammonia, 18F-DOPA, 11C-Methylreboxetine (11C-MRB) - Parkinson's Disease, Multiple System Atrophy
CompletedNational Institute of Neurological Disorders and Stroke (NINDS)892018-09-062026-10-26
Automated Abdominal Binder for Orthostatic Hypotension
automated abdominal binder, Sham binder, Placebo - Orthostatic Hypotension, Autonomic Failure
Phase 1 / Phase 2CompletedVanderbilt University Medical Center282018-03-012026-05-05
Treatment of Supine Hypertension in Autonomic Failure (CPAP)
continuous positive airway pressure (CPAP), Placebo - Supine Hypertension, Autonomic Failure
Not applicableRecruitingVanderbilt University Medical Center122017-09-212025-11-06
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
TD-9855, Placebo - Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension
Phase 2CompletedTheravance Biopharma342017-09-092022-09-26
Concentration and Attentional Deficits in POTS and Other Autonomic Neuropathies
leg crossing - Autonomic Failure, Dysautonomia
Not applicableCompletedRWTH Aachen University1102017-04-012023-06-26
Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension
Heating pad, Sham control - Hypertension, Pure Autonomic Failure
Not applicableRecruitingVanderbilt University Medical Center202017-01-302026-01-16

Showing 20 of 56. Sign in to see all of them.

Narrower conditions

Multiple System Atrophy (33)  ·  Parkinson Disease (22)  ·  Hypotension, Orthostatic (21)  ·  Hypertension (12)  ·  Autonomic Nervous System Diseases (6)  ·  Hypotension (6)  ·  Shy-Drager Syndrome (6)  ·  Lewy Body Disease (5)  ·  dopamine beta hydroxylase deficiency (5)  ·  Syncope (4)  ·  Dizziness (3)  ·  Parkinsonian Disorders (3)  ·  REM Sleep Behavior Disorder (3)  ·  Cognitive Dysfunction (2)

Broader conditions

Nervous System Diseases (56)  ·  Primary Dysautonomias (56)  ·  Autonomic Nervous System Diseases (50)  ·  Central Nervous System Diseases (43)  ·  Basal Ganglia Diseases (42)  ·  Brain Diseases (42)  ·  Movement Disorders (42)  ·  Neurodegenerative Diseases (39)  ·  Synucleinopathies (39)  ·  Cardiovascular Diseases (35)  ·  Vascular Diseases (35)  ·  Orthostatic Intolerance (23)  ·  Hypotension (21)  ·  Parkinsonian Disorders (20)  ·  Mental Disorders (7)

Interventions

Droxidopa (6)  ·  Midodrine (6)  ·  ampreloxetine (4)  ·  Carbidopa (3)  ·  Pseudoephedrine (3)  ·  Sugars (3)  ·  Atomoxetine Hydrochloride (2)  ·  Captopril (2)  ·  Drinking (2)  ·  Losartan (2)  ·  Metoprolol (2)  ·  Nebivolol (2)  ·  Saline Solution (2)  ·  Sildenafil Citrate (2)  ·  Sodium Chloride (2)

Sponsors

Vanderbilt University (12)  ·  Vanderbilt University Medical Center (11)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (5)  ·  Chelsea Therapeutics (4)  ·  Theravance Biopharma (4)  ·  H. Lundbeck A/S (2)  ·  NYU Langone Health (2)  ·  RWTH Aachen University (2)  ·  Albert Einstein College of Medicine (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  CND Life Sciences (1)  ·  Daniel Claassen (1)  ·  Ecole Polytechnique Fédérale de Lausanne (1)  ·  Hannover Medical School (1)  ·  Istituto Clinico Humanitas (1)

Countries

United States (45)  ·  Canada (7)  ·  Germany (7)  ·  Australia (5)  ·  France (5)  ·  New Zealand (5)  ·  Denmark (4)  ·  Italy (4)  ·  Portugal (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  Austria (3)  ·  Bulgaria (3)  ·  Estonia (3)  ·  Israel (3)

Top investigators

Italo Biaggioni, MD (17)  ·  David S Goldstein, M.D. (2)  ·  Horacio C Kaufmann, MD (2)  ·  Italo Biaggioni, M.D. (2)  ·  Luis E Okamoto, MD (2)  ·  Roy Freeman, MD (2)  ·  Alberto Vasquez, MD (1)  ·  Alex L Green, FRCS(SN) (1)  ·  Alvin McElveen, MD (1)  ·  Andrea Maier, Dr. (1)  ·  Andrea Maier, Dr. med. (1)  ·  Astrid J. Terkelsen, MD, DrMedSc, PhD, Professor (1)  ·  Brent Goodman, MD (1)

Results publications

PMID 11927799, PMID 12119802, PMID 15738343, PMID 18426998, PMID 27538531, PMID 28494751, PMID 33739123, PMID 42475649, PMID 10662747, PMID 10851208, PMID 11904109, PMID 12832331, PMID 12923400, PMID 15066944, PMID 15710782, PMID 16391172, PMID 16533484, PMID 17116758, PMID 17130304, PMID 17515447, PMID 17515448, PMID 19047577, PMID 19738158, PMID 20837887, PMID 22016786, PMID 22311903, PMID 22469621, PMID 22522612, PMID 22801444, PMID 23266540, PMID 25350981, PMID 27271310, PMID 28860128, PMID 29405350, PMID 33554315, PMID 33782836, PMID 34657222, PMID 35107750, PMID 35272481, PMID 35705801, PMID 36601916, PMID 37261636, PMID 37883190, PMID 38156524, PMID 39727053, PMID 41449577, PMID 42044642, PMID 9369256, PMID 9727818, PMID 9890307

NIH funding

R01HL144568 (3), 2018 (2), U54NS065736 (2), 2019 (1), P01HL056693 (1), R01DK079974 (1), R01HL161095 (1), UL1TR000445 (1)